Finding a new treatment for Alzheimer's disease by stabilizing brain proteins
Official title: Development of a MT-stabilizing agent for the treatment of tauopathies
Funded at University of California, San Diego · NIH-10942972 · Data updated 2026-11-12
This study is looking for new ways to help brain health by testing different compounds that could stop a protein linked to Alzheimer's from misfolding, which might lead to better treatments for people with Alzheimer's and similar conditions.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $2,309,108 |
| NIH project number | 1U01AG088051-01 |
| Project ID | NIH-10942972 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or other tauopathies.
✕Less likely to help
Patients with non-tauopathy related neurodegenerative diseases may not benefit from this research.
What this research studies
This research focuses on developing a new agent that stabilizes microtubules in the brain, which are essential for neuron function. The study aims to identify alternative compounds that can prevent the misfolding of tau protein, a key factor in Alzheimer's disease and other tauopathies. By testing these compounds in models of tauopathies, the researchers hope to improve brain health and cognitive function. If successful, this research could lead to new treatments for patients suffering from Alzheimer's and related conditions.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves cognitive function and slows the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promise with similar approaches, particularly with the compound epothilone D, which improved outcomes in animal models of tauopathies.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Ballatore, Carlo — University of California, San Diego
- Study coordinator: Ballatore, Carlo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.